<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03965000</url>
  </required_header>
  <id_info>
    <org_study_id>20190121-1930</org_study_id>
    <nct_id>NCT03965000</nct_id>
  </id_info>
  <brief_title>Human Solute Carrier Family 5 Member 2 (SLC5A2) Deficiency and the Glucagon-Incretin Axis</brief_title>
  <official_title>Human SLC5A2 Deficiency and the Glucagon-Incretin Axis: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sodium-glucose-cotransporter 2 (SGLT2) are a new type of oral antidiabetic drugs. SGLT2
      inhibitors increase the urinary glucose excretion and thereby decrease blood glucose levels.
      Beside their glucose lowering effects SGLT2 inhibitors showed beneficial effects on the
      cardiovascular health. But several studies in cell culture and mice showed that the
      physiological inhibition of glucagon after meal consumption is impaired when using SGLT2
      inhibitors.

      The patients carry a rare genetical disease called Familial renal glucosuria (FRG), a human
      model of life long SGLT2 inhibition. To elucidate the effects of partial and complete SGLT2
      inhibition in humans the investigators perform a mixed-meal tolerance test (MMTT), the gold
      standard for elucidation of insulin and glucagon dynamics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The index patient was referred to the Department of Internal Medicine I at the Medical
      University of Innsbruck for evaluation of unclear glucosuria in combination with normal blood
      glucose levels. The patient suffered from recurrent urinary tract infections and increased
      urinary frequency, showed a physiological hemoglobin A1c and no further signs of renal
      dysfunction. Sequencing of the SLC5A2 coding region confirmed that the patient was compound
      heterozygous for two SLC5A2 mutations. The patient is a mother of five healthy children which
      are willing to take part in the test. The children show a 50/50 distribution of the mother's
      mutations. The MMTT will take place after 48 hours of alcohol, sport abstinence and an
      overnight fasting period. The patients will be given 6 ml/kg body weight of a standardized
      liquid meal. Blood samples will be collected 10 minutes before consumption of the meal, at
      the time point of consumption and 15, 30, 60, 120, 150, 180, 210 and 240 minutes after
      consumption. At each time point six blood tubes will be taken, except at time point -10 and
      240 minutes, there is one sample more collected. The investigators aim to assess glucagon,
      insulin, c-peptide, gastric inhibitory polypeptide (GIP), Glucagon-like peptide-1 (GLP-1),
      Glucagon-like peptide-2 (GLP-2) levels.

      Glucose tolerance will be assessed by using the 4 hours area under the curve (AUC) for
      glucose. To evaluate the beta-cell function the 4h-AUC's for insulin, c-peptide and the
      4h-AUC insulin:glucose ratio will be calculated and compared. The calculation of the
      alpha-cell function will be performed with the AUC of glucagon and the AUC glucagon/glucose
      ratio. GIP, GLP-1 and GLP-2 will be determined using the AUC. The AUC's will be calculated by
      the trapezoidal method.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2019</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the glucagon-incretin axis.</measure>
    <time_frame>18 months</time_frame>
    <description>Glucose tolerance will be assessed by using the 4 hours area under the curve (AUC) for glucose.
Beta-cell function will be assessed by the 4h-AUC's for insulin, c-peptide and the 4h-AUC insulin:glucose ratio will be calculated and compared. The calculation of the alpha-cell function will be performed with the AUC of glucagon and the AUC glucagon/glucose ratio. GIP, GLP-1 and GLP-2 will be determined using the AUC. The AUC's will be calculated by the trapezoidal method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the gene expression</measure>
    <time_frame>18 months</time_frame>
    <description>By collecting blood samples for gene expression analysis before and after the test and comparing it to our healthy controls.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Familial Renal Glucosuria</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Patients carrying one or both mutations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Patients not carrying a mutation Familial renal glucosuria causing mutation in the SLC5A2 gene and without impaired glucose tolerance and type 1 or 2 diabetes mellitus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mixed-meal-tolerance-test</intervention_name>
    <description>To assess the dynamics of the glucagon-incretin axis we need to perform the MMTT. Thereby the patients need to consume a body weight adjusted, standardized meal and we draw blood at fixed time points over 4 hours.</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood samples acquired during the mixed-meal-tolerance-test
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        One compound heterozygous female index patient and four heterozygous children. The control
        group consists of age, sex and BMI matched participants from nearly the same area to avoid
        environmental factors.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years

          -  Capable of giving consent

          -  One or more SLC5A2 mutations leading to FRG

          -  Written consent

        Exclusion Criteria:

          -  Impaired glucose tolerance

          -  Diabetes mellitus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tyrol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Ebenbichler, MD, Prof.</last_name>
      <phone>+43 512 504 81394</phone>
      <email>mui-sponsor@i-med.ac.at</email>
    </contact>
    <investigator>
      <last_name>Christoph Ebenbichler, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clemens Engler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.</citation>
    <PMID>26378978</PMID>
  </reference>
  <reference>
    <citation>Rosenstein R, Hough A. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2016 Mar 17;374(11):1093-4. doi: 10.1056/NEJMc1600827.</citation>
    <PMID>26981944</PMID>
  </reference>
  <reference>
    <citation>Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2016 Mar 17;374(11):1094. doi: 10.1056/NEJMc1600827.</citation>
    <PMID>26981940</PMID>
  </reference>
  <reference>
    <citation>Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl UC, Woerle HJ. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014 Feb;124(2):499-508. doi: 10.1172/JCI72227. Epub 2014 Jan 27. Erratum in: J Clin Invest. 2014 Apr 1;124(4):1868.</citation>
    <PMID>24463454</PMID>
  </reference>
  <reference>
    <citation>Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thévenet J, Beaucamps C, Delalleau N, Popescu I, Malaisse WJ, Sener A, Deprez B, Abderrahmani A, Staels B, Pattou F. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015 May;21(5):512-7. doi: 10.1038/nm.3828. Epub 2015 Apr 20.</citation>
    <PMID>25894829</PMID>
  </reference>
  <reference>
    <citation>Pedersen MG, Ahlstedt I, El Hachmane MF, Göpel SO. Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells. Sci Rep. 2016 Aug 18;6:31214. doi: 10.1038/srep31214.</citation>
    <PMID>27535321</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2019</study_first_posted>
  <last_update_submitted>May 27, 2019</last_update_submitted>
  <last_update_submitted_qc>May 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SGLT2</keyword>
  <keyword>SLC5A2</keyword>
  <keyword>glucose metabolism</keyword>
  <keyword>glucagon</keyword>
  <keyword>incretin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycosuria, Renal</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

